targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer针对沉默延长因子2的激酶抑制增长和糖分会让阿霉素在肿瘤原位乳腺癌模型.pdfVIP

下载本文档

1
0
约8.8万字
约 12页
2017-09-12 发布于上海
举报
版权申诉

targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer针对沉默延长因子2的激酶抑制增长和糖分会让阿霉素在肿瘤原位乳腺癌模型.pdf

1、本文档共12页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer针对沉默延长因子2的激酶抑制增长和糖分会让阿霉素在肿瘤原位乳腺癌模型

Targeted Silencing of Elongation Factor 2 Kinase Suppresses Growth and Sensitizes Tumors to Doxorubicin in an Orthotopic Model of Breast Cancer 1 1 2 1 3 Ibrahim Tekedereli , S. Neslihan Alpay , Clint D. J. Tavares , Zehra E. Cobanoglu , Tamer S. Kaoud , Ibrahim Sahin1, Anil K. Sood4,5,6, Gabriel Lopez-Berestein1,5,6, Kevin N. Dalby2,3*, Bulent Ozpolat1,6* 1 Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, 2 Graduate Program in Cell and Molecular Biology, The University of Texas, Austin, Texas, United States of America, 3 Division of Medicinal Chemistry, College of Pharmacy, The University of Texas, Austin, Texas, United States of America, 4 Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, 5 Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America, 6 Center for RNAi and Non-Coding RNA, University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America Abstract Eukaryotic elongation factor 2 kinase (eEF-2K), through its phosphorylation of elongation factor 2 (eEF2), provides a mechanism by which cells can control the rate of the elongation phase of protein synthesis. The activity of eEF-2K is increased in rapidly proliferating malignant cells, is inhibited during mitosis, and may contribute to the promotion of autophagy in response to anti-cancer therapies. The purpose of this study was to examine the therapeutic potential of targeting eEF-2K in